While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.

Moderna slashed its 2025 revenue projection by $1bn on Monday, citing reduced demand for its Covid-19 and respiratory ...

Robert F. Kennedy Jr. petitioned the F.D.A. to revoke authorization of the shots at a time when they were in high demand and ...

researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

2 (Pfizer and Moderna) and JN.1 (Novavax ... they have become more like annual flu shots for a specific season than "booster shots" for COVID. The Centers for Disease Control and Prevention ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

The VDH and Scott are advocating for people to get their vaccinations before winter. Scott said he has received his COVID ...

Moderna and the European Commission have amended their agreement to convert contractually agreed doses of Moderna’s COVID-19 vaccine to the company’s ... million doses of Moderna’s bivalent COVID-19 ...

to two new-generation COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna, both targeting the new Omicron subvariants BA.4 and BA.5. The US regulator has cleared a 30 µg booster dose of a new ...